205 related articles for article (PubMed ID: 16630168)
1. A successful approach for the detection of Fabry patients in Argentina.
Rozenfeld PA; Tarabuso A; Ebner R; Ramallo G; Fossati CA
Clin Genet; 2006 Apr; 69(4):344-8. PubMed ID: 16630168
[TBL] [Abstract][Full Text] [Related]
2. Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes.
Ashton-Prolla P; Tong B; Shabbeer J; Astrin KH; Eng CM; Desnick RJ
J Investig Med; 2000 Jul; 48(4):227-35. PubMed ID: 10916280
[TBL] [Abstract][Full Text] [Related]
3. Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography.
Shabbeer J; Robinson M; Desnick RJ
Hum Mutat; 2005 Mar; 25(3):299-305. PubMed ID: 15712228
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of patients with Fabry disease in Argentina].
AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
[TBL] [Abstract][Full Text] [Related]
5. Fabry disease: twenty novel alpha-galactosidase A mutations causing the classical phenotype.
Ashley GA; Shabbeer J; Yasuda M; Eng CM; Desnick RJ
J Hum Genet; 2001; 46(4):192-6. PubMed ID: 11322659
[TBL] [Abstract][Full Text] [Related]
6. Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches.
Germain DP; Poenaru L
Biochem Biophys Res Commun; 1999 Apr; 257(3):708-13. PubMed ID: 10208848
[TBL] [Abstract][Full Text] [Related]
7. Remarkable variability in renal disease in a large Slovenian family with Fabry disease.
Verovnik F; Benko D; Vujkovac B; Linthorst GE
Eur J Hum Genet; 2004 Aug; 12(8):678-81. PubMed ID: 15162124
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene.
Eng CM; Desnick RJ
Hum Mutat; 1994; 3(2):103-11. PubMed ID: 7911050
[TBL] [Abstract][Full Text] [Related]
9. [alpha-Galactosidase gene mutation and its expression product in Fabry disease (alpha-galactosidase deficiency)].
Okumiya T; Takata T; Sasaki M; Sakuraba H
Rinsho Byori; 1997 Feb; 45(2):127-35. PubMed ID: 9120996
[TBL] [Abstract][Full Text] [Related]
10. A case of multiple angiomas without any angiokeratomas in a female heterozygote with Fabry disease.
Mirceva V; Hein R; Ring J; Möhrenschlager M
Australas J Dermatol; 2010 Feb; 51(1):36-8. PubMed ID: 20148840
[TBL] [Abstract][Full Text] [Related]
11. A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population.
Merta M; Reiterova J; Ledvinova J; Poupetová H; Dobrovolny R; Rysavá R; Maixnerová D; Bultas J; Motán J; Slivkova J; Sobotova D; Smrzova J; Tesar V
Nephrol Dial Transplant; 2007 Jan; 22(1):179-86. PubMed ID: 17040996
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel point mutation (S65T) in alpha-galactosidase A gene in Chinese patients with Fabry disease. Mutations in brief no. 169. Online.
Chen CH; Shyu PW; Wu SJ; Sheu SS; Desnick RJ; Hsiao KJ
Hum Mutat; 1998; 11(4):328-30. PubMed ID: 9554750
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma.
Froissart R; Guffon N; Vanier MT; Desnick RJ; Maire I
Mol Genet Metab; 2003 Nov; 80(3):307-14. PubMed ID: 14680977
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.
Yasuda M; Shabbeer J; Benson SD; Maire I; Burnett RM; Desnick RJ
Hum Mutat; 2003 Dec; 22(6):486-92. PubMed ID: 14635108
[TBL] [Abstract][Full Text] [Related]
15. Alport syndrome. Molecular genetic aspects.
Hertz JM
Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy.
Monserrat L; Gimeno-Blanes JR; Marín F; Hermida-Prieto M; García-Honrubia A; Pérez I; Fernández X; de Nicolas R; de la Morena G; Payá E; Yagüe J; Egido J
J Am Coll Cardiol; 2007 Dec; 50(25):2399-403. PubMed ID: 18154965
[TBL] [Abstract][Full Text] [Related]
17. Disease manifestations and X inactivation in heterozygous females with Fabry disease.
Maier EM; Osterrieder S; Whybra C; Ries M; Gal A; Beck M; Roscher AA; Muntau AC
Acta Paediatr Suppl; 2006 Apr; 95(451):30-8. PubMed ID: 16720462
[TBL] [Abstract][Full Text] [Related]
18. A missense mutation, A156T, in the alpha-galactosidase A gene causes typical Fabry disease.
Konoshita T; Mutoh H; Yokoi T; Koni I; Miyamori I; Mabuchi H
Clin Nephrol; 2001 Mar; 55(3):243-7. PubMed ID: 11316246
[TBL] [Abstract][Full Text] [Related]
19. Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population.
Terryn W; Poppe B; Wuyts B; Claes K; Maes B; Verbeelen D; Vanholder R; De Boeck K; Lameire N; De Paepe A; De Schoenmakere G
Nephrol Dial Transplant; 2008 Jan; 23(1):294-300. PubMed ID: 17804462
[TBL] [Abstract][Full Text] [Related]
20. [Molecular genetics of inherited metabolic diseases--its application to the investigation of pathogenesis and the diagnosis of Fabry disease].
Sakuraba H
Rinsho Byori; 1994 Jun; 42(6):628-35. PubMed ID: 7914243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
